A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations

Publication date: Available online 7 July 2021Source: Cell ReportsAuthor(s): Federico Bertoglio, Viola Fühner, Maximilian Ruschig, Philip Alexander Heine, Leila Abassi, Thomas Klünemann, Ulfert Rand, Doris Meier, Nora Langreder, Stephan Steinke, Rico Ballmann, Kai-Thomas Schneider, Kristian Daniel Ralph Roth, Philipp Kuhn, Peggy Riese, Dorina Schäckermann, Janin Korn, Allan Koch, M. Zeeshan Chaudhry, Kathrin Eschke

Source: Cell Reports - July 7, 2021 Category: Cytology Source Type: research